Vanguard Group Inc. has significantly bolstered its investment in Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company known for its development of antibody drug conjugates (ADCs). According to the most recent 13F filing with the Securities and Exchange Commission (SEC), Vanguard
Arbutus Biopharma Corporation (NASDAQ: ABUS), the biopharmaceutical company known for its focus on developing treatments for chronic Hepatitis B virus (HBV) infection, recently received a noteworthy boost in its stock price target. JMP Securities raised its price objective from $4.00 to $5.00,
Xeris Biopharma Holdings Inc. (NASDAQ: XERS) recently experienced a slight dip in its stock value, closing at $2.48, down -1.59% from the previous day. However, with positive analyst ratings, significant insider buying, and strong institutional support, there are several optimistic indicators for
Global Automation in Biopharma Market to Surge by 2031: Key Trends and Forecasts The global biopharma market is on the cusp of remarkable transformations driven by automation, enabling more efficient production processes and improved product quality. This evolving sector is undergoing significant
AbbVie's financial performance and strategic initiatives in 2022 demonstrate a concerted effort to drive growth and enhance its presence in the pharmaceutical and biopharmaceutical sectors. With revenues exceeding $58 billion, the year reflected significant advancements fueled by new product
The biopharma industry is abuzz with rumors of a potential takeover of CAR-T specialist Legend Biotech, a company renowned for its collaboration with Johnson & Johnson (J&J) on the BCMA CAR-T therapy Carvykti. An unnamed source cited by StreetInsider has revealed that Legend recently received a
